PMID- 35223996
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220301
IS  - 2296-889X (Print)
IS  - 2296-889X (Electronic)
IS  - 2296-889X (Linking)
VI  - 9
DP  - 2022
TI  - N6-Methyladenosine Methylation Regulator RBM15 is a Potential Prognostic 
      Biomarker and Promotes Cell Proliferation in Pancreatic Adenocarcinoma.
PG  - 842833
LID - 10.3389/fmolb.2022.842833 [doi]
LID - 842833
AB  - RNA binding motif protein 15 (RBM15) is a key regulatory factor involved in 
      N6-methyladenosine (m6A) methylation. It has been reported that RBM15 plays an 
      important role in the progress of laryngeal squamous cell carcinoma (LSCC), 
      promoting LSCC migration and invasion. However, the role of RBM15 in human 
      different cancers remains unknown. This study aims to analyze the prognostic 
      value of RBM15, and to demonstrate the correlation between RBM15 expression and 
      tumor immunity, as well as to provide clues for further mechanism research. The 
      results showed that RBM15 was mutated or copy number varied in 25 types of 
      cancer. RBM15 mRNA was abnormally up-regulated across various cancers. Survival 
      analysis suggested high expression of RBM15 was associated with poor prognosis in 
      many cancer types. Among these, it affected patients' overall survival (OS) in 10 
      cancer types, disease-free interval (DFI) in 8 cancer types, progression-free 
      interval (PFI) in 12 cancer types and disease-specific survival (DSS) in 7 cancer 
      types. Importantly, in pancreatic adenocarcinoma (PAAD), overexpression of RBM15 
      is associated with patients' OS, DFI, PFI, or DSS. In addition, RBM15 expression 
      was positively correlated with immune infiltrating cells in kidney renal clear 
      cell carcinoma (KIRC), brain lower grade glioma (LGG), and PAAD. Moreover, RBM15 
      expression showed a strong correlation with immune checkpoint markers in PAAD. 
      Cell counting kit-8 (CCK-8) assay showed that knockdown of RBM15 significantly 
      inhibited the proliferation of pancreatic cancer cells. PPI analysis showed 
      USP10, USP24, SMG1, NRAS were closely connected with RBM15 alterations. Gene 
      Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed 
      that many biological processes (BP), cellular components (CC), molecular 
      functions (MF), cancer related pathways including "sister chromatid cohesion", 
      "peptidyl-serine phosphorylation", "cell division", "nucleoplasm", "nucleus", 
      "protein binding", "protein serine/threonine kinase activity", "T cell receptor 
      signaling pathway", "Cell cycle" were regulated by RBM15 alterations. Taken 
      together, pan-cancer analysis of RBM15 suggested it may be served as a prognostic 
      biomarker and immunotherapeutic target for PAAD.
CI  - Copyright (c) 2022 Zhao, Ju, Ji, Li and Zhao.
FAU - Zhao, Zhiying
AU  - Zhao Z
AD  - School of Public Health, Qingdao University, Qingdao, China.
FAU - Ju, Qiang
AU  - Ju Q
AD  - Department of Blood Transfusion, The Affiliated Hospital of Qingdao University, 
      Qingdao, China.
FAU - Ji, Jing
AU  - Ji J
AD  - School of Public Health, Qingdao University, Qingdao, China.
FAU - Li, Yutong
AU  - Li Y
AD  - School of Public Health, Qingdao University, Qingdao, China.
FAU - Zhao, Yanjie
AU  - Zhao Y
AD  - School of Public Health, Qingdao University, Qingdao, China.
LA  - eng
PT  - Journal Article
DEP - 20220209
PL  - Switzerland
TA  - Front Mol Biosci
JT  - Frontiers in molecular biosciences
JID - 101653173
PMC - PMC8864094
OTO - NOTNLM
OT  - RBM15
OT  - genomic alteration
OT  - immunity
OT  - prognosis
OT  - proliferation
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/03/01 06:00
MHDA- 2022/03/01 06:01
PMCR- 2022/01/01
CRDT- 2022/02/28 05:40
PHST- 2021/12/24 00:00 [received]
PHST- 2022/01/24 00:00 [accepted]
PHST- 2022/02/28 05:40 [entrez]
PHST- 2022/03/01 06:00 [pubmed]
PHST- 2022/03/01 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 842833 [pii]
AID - 10.3389/fmolb.2022.842833 [doi]
PST - epublish
SO  - Front Mol Biosci. 2022 Feb 9;9:842833. doi: 10.3389/fmolb.2022.842833. 
      eCollection 2022.